Gyre Therapeutics Inc. (GYRE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Gyre Therapeutics Inc. (GYRE) has a cash flow conversion efficiency ratio of 0.023x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($3.18 Million) by net assets ($136.99 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Gyre Therapeutics Inc. defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Gyre Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Gyre Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Gyre Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Gyre Therapeutics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanghai Sanyou Medical Co Ltd
SHG:688085
|
0.016x |
|
SmartFinancial, Inc.
NASDAQ:SMBK
|
0.031x |
|
Dexus Convenience Retail REIT
AU:DXC
|
0.029x |
|
Yes Optoelectronics Co Ltd Class A
SHE:002952
|
-0.010x |
|
HelloFresh SE
XETRA:HFG
|
0.201x |
|
Chularat Hospital Public Company Limited
BK:CHG-R
|
0.040x |
|
PRINC.PR.EQ.HLDGS EO-001
F:PEYA
|
N/A |
|
Musti Group Oyj
HE:MUSTI
|
0.079x |
Annual Cash Flow Conversion Efficiency for Gyre Therapeutics Inc. (2004–2025)
The table below shows the annual cash flow conversion efficiency of Gyre Therapeutics Inc. from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see GYRE market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $142.28 Million | $1.01 Million | 0.007x | +119.18% |
| 2024-12-31 | $98.40 Million | $-3.64 Million | -0.037x | -101.99% |
| 2023-12-31 | $13.95 Million | $25.89 Million | 1.856x | +1155.49% |
| 2022-12-31 | $72.22 Million | $10.68 Million | 0.148x | +107.25% |
| 2021-12-31 | $41.09 Million | $-83.75 Million | -2.038x | -181.68% |
| 2020-12-31 | $76.07 Million | $-55.05 Million | -0.724x | -13.39% |
| 2019-12-31 | $68.34 Million | $-43.61 Million | -0.638x | -168.10% |
| 2018-12-31 | $119.94 Million | $-28.55 Million | -0.238x | +63.26% |
| 2017-12-31 | $30.77 Million | $-19.94 Million | -0.648x | +43.63% |
| 2016-12-31 | $16.07 Million | $-18.47 Million | -1.149x | -88.93% |
| 2015-12-31 | $31.43 Million | $-19.12 Million | -0.608x | -92.45% |
| 2014-12-31 | $109.08 Million | $-34.48 Million | -0.316x | -4.78% |
| 2013-12-31 | $134.61 Million | $-40.61 Million | -0.302x | +17.38% |
| 2012-12-31 | $175.91 Million | $-64.24 Million | -0.365x | +23.98% |
| 2011-12-31 | $174.29 Million | $-83.72 Million | -0.480x | -131.90% |
| 2010-12-31 | $91.85 Million | $138.30 Million | 1.506x | +528.01% |
| 2009-12-31 | $68.99 Million | $-24.27 Million | -0.352x | +28.58% |
| 2008-12-31 | $57.37 Million | $-28.26 Million | -0.493x | -202.30% |
| 2007-12-31 | $51.58 Million | $24.84 Million | 0.482x | +416.38% |
| 2006-12-31 | $65.00 Million | $-9.89 Million | -0.152x | -194.22% |
| 2005-12-31 | $-162.48 Million | $-26.25 Million | 0.162x | -20.66% |
| 2004-12-31 | $-122.97 Million | $-25.04 Million | 0.204x | -- |
About Gyre Therapeutics Inc.
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in th… Read more